Last reviewed · How we verify
Tafamidis meglumin
Tafamidis meglumin is a Small molecule drug developed by Pfizer. It is currently FDA-approved. Also known as: PF-06291826.
Tafamidis meglumin is a small molecule that stabilizes transthyretin. It is classified as a stabilizer.
At a glance
| Generic name | Tafamidis meglumin |
|---|---|
| Also known as | PF-06291826 |
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tafamidis meglumin CI brief — competitive landscape report
- Tafamidis meglumin updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Tafamidis meglumin
What is Tafamidis meglumin?
Tafamidis meglumin is a Small molecule drug developed by Pfizer.
Who makes Tafamidis meglumin?
Tafamidis meglumin is developed and marketed by Pfizer (see full Pfizer pipeline at /company/pfizer).
Is Tafamidis meglumin also known as anything else?
Tafamidis meglumin is also known as PF-06291826.
What development phase is Tafamidis meglumin in?
Tafamidis meglumin is FDA-approved (marketed).
Related
- Manufacturer: Pfizer — full pipeline
- Also known as: PF-06291826
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing